Leronlimab
As of the edition of 20 October 2026, Leronlimab is an antibody: in active development; acts on CCR5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Antibody
- Registered trials
- 24, 7 stopped early
- Disease areas
- Infections; Immune system; Cancer; Lungs and airways; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CCR5 | C-C chemokine receptor type 5 | P51681 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 14 | 7 | 2 | 5 |
| Phase 3 | 6 | 2 | 0 | 2 |
| All trials | 24 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CytoDyn | Lead sponsor of trials |